Clinical trials: Enteric Fever
Vaccine
Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian
Vi-DT Typhoid vaccine is a novel vaccine. This study will be done to know the long-term protection and persistent antibody by measured the antibody titer after 2,3,4 and 5 years after immunization.
- Trial name
- NCT04741828
- Testing
- Vi-DT Typhoid Conjugate Vaccine
- Where
- 2 sites in Indonesia
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Typhoid
Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi
This study will evaluate the efficacy of a Typhoid conjugate vaccine (Vi-TCV) in Malawi, Africa among children age 9 months through 12 years.
- Trial name
- NCT03299426
- Testing
- Vi-Typhoid Conjugate Vaccine (Vi-TCV), Meningococcal A Conjugate Vaccine (MCV-A)
- Where
- Malawi
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Typhoid
Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine
This is a Multicenter, observer-blinded, randomized, Active controlled, Phase 3 study in healthy 6 months to 45 years aged Nepalese at the time of the first vaccine dose. The study objectives are: I.
- Trial name
- NCT03933098
- Testing
- Test Vaccine Vi-DT Typhoid conjugate, Control Vaccine Typbar TCV®
- Where
- 4 sites in Nepal
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid Fever, Paratyphoid Fever
Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge Study
Enteric fever, an infection characterised by diarrhoea and rash, is most often caused by a bacteria called Salmonella enterica. After ingesting contaminated food or drink, the Salmonellae travel first to the gut, then the…
- Trial name
- NCT02192008
- Testing
- Salmonella Typhi, Salmonella Paratyphi
- Where
- United Kingdom
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Healthy
Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines
In a recent controlled study, the investigators explored cross-reactive immune responses against different Salmonella spp. in healthy volunteers immunized with either the oral (Vivotif® ) or parenteral (Typherix®) typhoid…
- Trial name
- Ty21a-ASC (NCT02121145)
- Testing
- Vivotif, Typherix
- Where
- 3 sites in Finland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Enteric Fever, Acute Febrile Illness
Transcriptomic Responses for the Identification of Pathogens
Acute undifferentiated febrile infection (AUFI) is a common presenting syndrome in low-resource settings and better diagnostics are urgently needed to improve patient management and guide disease prevention interventions.
- Conditions
- Enteric Fever, Acute Febrile Illness, Typhoid, Paratyphoid Fever
- Trial name
- TRiP (NCT04878549)
- Testing
- 5-gene transcription signature
- Where
- India
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of Sheffield
Typhoid Fever
Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers
This is a multicenter (at travel clinics), phase 4 observational prospective cohort study in healthy adult male and female travelers for whom typhoid vaccination with Vivotif is recommended, as per standard practice.
- Trial name
- NCT02391909
- Testing
- Vivotif
- Where
- United States
- Volunteers
- 855 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Safety Issues, Immunogenicity
Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)
Phase III study, Randomized, observer blind, lot to lot consistency, non inferiority to PQed typhoid conjugate vaccine and Typhoid Vi polysaccharide vaccine.
- Trial name
- NCT04051268
- Testing
- Vi-DT Typhoid Conjugate Vaccine, PQed Typhoid Conjugate Vaccine, Vi Polysaccharide Vaccine
- Where
- Indonesia
- Volunteers
- 3,071 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Typhoid, Paratyphoid Fever
Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever
This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00125008
- Testing
- Typhoid Vi vaccine, Hepatitis A vaccine
- Where
- India
- Volunteers
- 37,673 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid, Paratyphoid Fever
Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood
This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00125047
- Testing
- Typhoid Vi vaccine, Hepatitis A vaccine
- Where
- Pakistan
- Volunteers
- 27,231 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid Fever
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
This trial is aimed to evaluate the safety and immunogenicity profiles of a new Vi-CRM197 conjugate vaccine against S. Typhi in healthy human adults in comparison with the currently licensed Vi polysaccharide vaccine.
- Trial name
- NCT01123941
- Testing
- Typherix, NVGH Vi-CRM197
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novartis
Antibody Typhoid Vaccine
Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV
Typhoid fever is a serious systemic infection caused by the enteric pathogen Salmonella enterica serovar typhi. S typhi is spread by the fecal-oral route. Although largely an endemic disease, S. typhi has epidemic potential.
- Trial name
- NCT06921460
- Where
- Indonesia
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Typhoid Vaccine on Sleep
Investigating the Effects of Typhoid Vaccine on Sleep in Healthy Volunteers
Research studies have found a relationship between the immune system (how the body reacts to an infection) and the development of depression.
- Trial name
- NCT02628054
- Testing
- Typhoid Vaccine
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Typhoid Fever
Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults
The purpose of this study is to evaluate the immunogenicity and the kinetics of the anti-Vi antibody response following secondary vaccination with the Novartis Vaccines Institute for Global Health (NVGH) Vi-CRM197 vaccine in…
- Trial name
- NCT01438996
- Testing
- NVGH Vi-CRM197
- Where
- Belgium
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Novartis
Salmonella Infection Non-Typhoid
Interaction Between Non-typhoid Salmonella, Host Microbiota, and Immune System During Acute Infection and Remission
Stool and blood samples from patients with a non-typhoid Salmonella infection will be collected during an observation period of six months and analyzed for changes in the microbiota diversity and composition, mutation rates in…
- Trial name
- NCT03494101
- Testing
- Blood samples, Stool samples, Clinical information
- Where
- Switzerland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Acute Watery Diarrhea, Dysentery/Febrile Diarrhea
Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea
The purpose of the trial is to develop the evidence on relative efficacy of 3 available single-dose loperamide adjuncted regimens for watery diarrhea and a single-dose regimen, with and without loperamide, for dysentery/febrile…
- Trial name
- TrEAT TD (NCT01618591)
- Testing
- Single dose rifaximin 1650 mg, Single dose azithromycin 500 mg, Single dose levofloxacin 500 mg
- Where
- 5 sites in Afghanistan, Djibouti and 3 more
- Volunteers
- 384 people
- Sponsor
- Uniformed Services University of the Health Sciences
Typhoid
Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso
Typhoid fever is an illness that may cause mild effects in children, such as fever and feeling tired, or it may cause serious effects-- even death.
- Trial name
- NCT03614533
- Testing
- Vi-Typhoid Conjugate Vaccine (Vi-TCV), Inactivated Poliovirus Vaccine (IPV)
- Where
- Burkina Faso
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Salmonella Infections
A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever
The purpose of this study is to assess the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid…
- Trial name
- NCT05480800
- Testing
- Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose, Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose, Typhoid conjugate vaccine (TCV) low dose
- Where
- 2 sites in Belgium, Malawi
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Typhoid Fever
Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)
This trial is aimed to evaluate the safety and immunogenicity profiles of three formulations of Vi-CRM197 conjugate vaccine against S.
- Trial name
- NCT01193907
- Testing
- NVGH Vi-CRM197 12.5 mcg, NVGH Vi-CRM197 5.0 mcg, NVGH Vi-CRM197 1.25 mcg
- Where
- Belgium
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novartis
Typhoid
Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine
This is a Phase I, Randomized, observer-blinded, age de-escalating study. The study objectives are: 1. To evaluate the safety of 25 μg of Vi-DT typhoid conjugate vaccine administered at 0 and 4 weeks. 2.
- Trial name
- NCT02645032
- Testing
- Vi-DT, Typhim Vi®, VAXIGRIP®
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute